Mesoblast shares (ASX:MSB) closed sharply lower on Friday despite reporting a sixteen-fold revenue increase, as markets digested mixed signals about the biotech’s commercial momentum and path to profitability.
The Mesoblast share price highlighted some serious intraday volatility, opening at A$2.63 before surrendering early gains to close at A$2.24, down 7.44% on the day. The approximately 15% intraday swing reflected conflicting interpretations of the company’s half-year results, with the selloff extending Mesoblast’s difficult 2026 start to a 19.13% year-to-date decline.
The price action on what appeared a strong print suggests markets may have anticipated stronger second-half growth guidance than the company provided.
Financials Improving
For the six months ended December 31, 2025, Mesoblast reported total revenue of US$51.3 million, a substantial jump from US$3.2 million in the prior corresponding period. The dramatic increase was driven almost entirely by Ryoncil, the company’s approved treatment for pediatric steroid-refractory acute graft-versus-host disease, which generated gross sales of US$57 million and net revenue of US$48.7 million after adjustments.
The product delivered gross profit of US$44.2 million excluding amortisation during the half, demonstrating strong unit economics as the commercial launch gains traction. Quarterly momentum accelerated through the period, with Ryoncil gross sales reaching US$35 million in the December quarter alone, representing 60% growth from the prior quarter.
Top Australian Brokers
- Pepperstone - Top Australian broker - Read our review
- eToro - Invest in ASX and international shares - Read our review
Despite the revenue surge, Mesoblast remains unprofitable, reporting a net loss of US$40.2 million for the half. However, this represented a meaningful improvement from the US$47.9 million loss recorded in the prior corresponding period, suggesting the company is moving toward breakeven as revenue scales.
Balance Sheet Strengthened
Mesoblast ended the period with US$130 million in cash and successfully executed a strategic refinancing that strengthens its financial position. The company secured a US$125 million five-year non-dilutive credit facility from its largest shareholder, which it used to repay existing senior secured debt and partially retire a subordinated royalty facility.
The new facility carries a fixed interest rate of 8% per annum and notably does not encumber Mesoblast’s material assets or intellectual property, providing greater flexibility for future strategic partnerships and commercial expansion. The refinancing is expected to lower the company’s overall cost of capital while extending its financial runway.
Guidance and Pipeline Progress
Looking ahead, Mesoblast guided to full-year FY2026 Ryoncil net revenue between US$110 million and US$120 million. While representing continued strong growth, the guidance implies second-half revenue of approximately US$61-69 million, suggesting sequential growth will moderate from the 60% quarter-over-quarter pace achieved in December. This deceleration may explain Friday’s market reaction.
Beyond its commercial product, Mesoblast is advancing a confirmatory Phase 3 trial for rexlemestrocel-L in chronic low back pain. The trial is actively recruiting across 40 U.S. sites, with enrollment expected to complete in March or April 2026. Data readout and a Biologics License Application filing are anticipated in 2027, with the FDA indicating that a clinically meaningful reduction in pain intensity at 12 months can support product efficacy for approval.
The company is also planning a pivotal trial to expand Ryoncil’s use to adult steroid-refractory acute graft-versus-host disease patients, a market approximately three times larger than the current pediatric segment, representing a significant commercial opportunity if successful.
Bull Case:
- Ryoncil revenue surged sixteen-fold with strong quarterly acceleration showing commercial momentum
- Gross profit margins exceeding 90% demonstrate highly attractive unit economics
- US$125 million non-dilutive credit facility extends runway without shareholder dilution
- Adult acute graft-versus-host disease market represents three-times expansion opportunity
- Net losses narrowing 16% year-over-year suggests path to profitability emerging
Bear Case:
- Full-year guidance implies moderating sequential growth in second half of year
- Company remains unprofitable with US$40 million half-year loss despite revenue surge
- Year-to-date share price decline of 19% reflects persistent market skepticism
- Pipeline success dependent on unproven Phase 3 trial outcomes in 2027
- Reliance on debt financing creates fixed obligations despite improving revenue trajectory
Friday’s volatile trading session highlights the split on the Street as far as Mesoblast shares are concerned. A company that is seen to be delivering impressive commercial traction, but still navigating the challenging transition from development-stage biotech to sustainable profitability. With a strengthened balance sheet and accelerating revenue, the company appears well-positioned, though markets will demand consistent proof that growth can be sustained while losses continue to narrow toward the breakeven threshold.
